IN THE CLAIMS:

Please cancel claims 1-3, 5, 8-10, 13, 27-33, 36, 37 without prejudice or disclaimer.

7. (Twice amended) A method for administering a recombinant adenoviruses containing a gene of interest to a human subject believed to be in need of said method, comprising providing a human subject with antibodies directed to an adenovirus of the same serotype or cross-reactive with the same serotype as the recombinant adenovirus containing the gene of interest, before administration of the recombinant adenovirus containing the gene of interest.

34. (Amended) The method of claim 38, wherein said administration of the recombinant adenovirus containing the gene of interest occurs at least fourteen days after said human subject is provided with antibodies directed to an adenovirus of the same serotype or cross-reactive with the same serotype as the recombinant adenovirus containing the gene of interest.

35. (Amended) The method of claim 7, further comprising providing a second dose of said antibodies directed to an adenovirus of the same serotype or cross-reactive with the same serotype as the recombinant adenovirus containing the gene of interest prior to said administrating said recombinant adenovirus containing the gene of interest.

Please add the following new claims:

38. (New) The method according to claim 7, wherein the subject is provided with the antibodies by first administering, to said human subject, a first adenovirus of the same serotype as the recombinant adenovirus, at a time before administration of a recombinant adenovirus containing a gene of interest, to induce in the subject an immune response against the adenovirus.

39. (New) The method according to claim 7, wherein said human subject is provided with

said antibodies by administering, to said human subject, antibodies directed against the same serotype of adenovirus as the recombinant adenovirus or antibodies cross-reactive with the serotype of the recombinant adenovirus.

C3 Cont

40. (New) The method according to claim 39, wherein said antibodies are provided to said human subject about one hour before administration of said recombinant adenovirus containing the gene of interest.